{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:26:36Z","timestamp":1779215196001,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40744-025-00748-8","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T15:21:49Z","timestamp":1740756109000},"page":"381-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Synergistic Improvements in Synovitis, Enthesitis, and Patient-Reported Outcomes for Patients with Psoriatic Arthritis Treated with Ixekizumab in SPIRIT Trials"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct01695239","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02349295","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03151551","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lars-Erik","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Rudwaleit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Adler","family":"W\u00fcrtzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Ngantcha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Holzk\u00e4mper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"748_CR1","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.12688\/f1000research.19144.1","volume":"8","author":"DV Ocampo","year":"2019","unstructured":"Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:1665.","journal-title":"F1000Res"},{"issue":"6","key":"748_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"748_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"748_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","volume":"14","author":"T Gudu","year":"2018","unstructured":"Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(5):405\u201317.","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 11","key":"748_CR5","first-page":"S64","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Measures of psoriatic arthritis: tender and Swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander\/Newcastle enthesitis index (MEI), Leeds enthesitis index (LEI), Spondyloarthritis research consortium of Canada (SPARCC), Maastricht ankylosing spondylitis enthesis score (MASES), Leeds dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S64-85.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"748_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00296-019-04480-9","volume":"40","author":"I Sunar","year":"2020","unstructured":"Sunar I, et al. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study. Rheumatol Int. 2020;40(2):283\u201394.","journal-title":"Rheumatol Int"},{"issue":"12","key":"748_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","volume":"13","author":"G Schett","year":"2017","unstructured":"Schett G, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13(12):731\u201341.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"748_CR8","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/art.22758","volume":"56","author":"D McGonagle","year":"2007","unstructured":"McGonagle D, Lories RJU, Tan AL, Benjamin M. The concept of a \u201csynovio-entheseal complex\u201d and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007;56(8):2482\u201391.","journal-title":"Arthritis Rheum"},{"issue":"SI","key":"748_CR9","doi-asserted-by":"publisher","first-page":"SI92","DOI":"10.1093\/rheumatology\/keab764","volume":"61","author":"P Bosch","year":"2022","unstructured":"Bosch P, et al. The role of tender and swollen joints for the assessment of inflammation in PsA using ultrasound. Rheumatology (Oxford). 2022;61(SI):SI92\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"748_CR10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1136\/annrheumdis-2019-215321","volume":"78","author":"HB Hammer","year":"2019","unstructured":"Hammer HB, et al. Swollen, but not tender joints, are independently associated with ultrasound synovitis: results from a longitudinal observational study of patients with established rheumatoid arthritis. Ann Rheum Dis. 2019;78(9):1179\u201385.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"748_CR11","doi-asserted-by":"publisher","first-page":"rkab086","DOI":"10.1093\/rap\/rkab086","volume":"5","author":"SR Dubash","year":"2021","unstructured":"Dubash SR, et al. Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naive early psoriatic arthritis. Rheumatol Adv Pract. 2021;5(3):rkab086.","journal-title":"Rheumatol Adv Pract"},{"issue":"4","key":"748_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11926-011-0181-y","volume":"13","author":"AW van Kuijk","year":"2011","unstructured":"van Kuijk AW, Tak PP. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep. 2011;13(4):353\u20139.","journal-title":"Curr Rheumatol Rep"},{"key":"748_CR13","unstructured":"FDA, Highlights of prescribing information, in TALTZ (ixekizumab) injection, for subcutaneous use 2022."},{"issue":"10","key":"748_CR14","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","volume":"59","author":"V Chandran","year":"2020","unstructured":"Chandran V, et al. Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase\u00a0III clinical trial (SPIRIT-P1). Rheumatology (Oxford). 2020;59(10):2774\u201384.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"748_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40744-020-00261-0","volume":"8","author":"AM Orbai","year":"2021","unstructured":"Orbai AM, et al. Efficacy and safety of ixekizumab in patients with psoriatic arthritis and inadequate response to TNF inhibitors: 3-year follow-up (SPIRIT-P2). Rheumatol Ther. 2021;8(1):199\u2013217.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"748_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s40744-020-00250-3","volume":"7","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, et al. Efficacy and safety of ixekizumab with or without methotrexate in biologic-naive patients with psoriatic arthritis: 52-week results from SPIRIT-H2H study. Rheumatol Ther. 2020;7(4):1021\u201335.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"748_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.170429","volume":"45","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase\u00a0III study (SPIRIT-P1). J Rheumatol. 2018;45(3):367\u201377.","journal-title":"J Rheumatol"},{"issue":"1","key":"748_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase\u00a0III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"748_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","volume":"21","author":"DD Gladman","year":"2019","unstructured":"Gladman DD, et al. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase\u00a03 randomized trials in psoriatic arthritis. Arthritis Res Ther. 2019;21(1):38.","journal-title":"Arthritis Res Ther"},{"issue":"10086","key":"748_CR20","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase\u00a03 trial. Lancet. 2017;389(10086):2317\u201327.","journal-title":"Lancet"},{"issue":"1","key":"748_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"748_CR22","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/acr.23249","volume":"69","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, et al. Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the corrona psoriatic arthritis\/spondyloarthritis registry. Arthritis Care Res (Hoboken). 2017;69(11):1692\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"748_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/rheumatology\/keu328","volume":"54","author":"D McGonagle","year":"2015","unstructured":"McGonagle D, Hermann KG, Tan AL. Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology (Oxford). 2015;54(1):29\u201338.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"748_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/annrheumdis-2018-213826","volume":"78","author":"M Kloppenburg","year":"2019","unstructured":"Kloppenburg M, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"748_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/rheumatology\/kex079","volume":"57","author":"A Marchesoni","year":"2018","unstructured":"Marchesoni A, et al. The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology (Oxford). 2018;57(1):32\u201340.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"748_CR26","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1093\/rheumatology\/keab784","volume":"61","author":"F Behrens","year":"2022","unstructured":"Behrens F, et al. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase\u00a03b trial. Rheumatology (Oxford). 2022;61(7):2856\u201366.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"748_CR27","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1007\/s12325-022-02269-0","volume":"39","author":"JR Curtis","year":"2022","unstructured":"Curtis JR, et al. The effect of guselkumab on general health state in biologic-naive patients with active psoriatic arthritis through week\u00a052 of the phase\u00a03, randomized, placebo-controlled DISCOVER-2 trial. Adv Ther. 2022;39(10):4632\u201344.","journal-title":"Adv Ther"},{"issue":"9","key":"748_CR28","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","volume":"78","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 2019;78(9):1215\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6 Suppl 1","key":"748_CR29","first-page":"52","volume":"49","author":"LC Coates","year":"2022","unstructured":"Coates LC, et al. GRAPPA treatment recommendations: 2021 update. J Rheumatol. 2022;49(6 Suppl 1):52\u20134.","journal-title":"J Rheumatol"},{"issue":"6","key":"748_CR30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"748_CR31","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s40744-021-00377-x","volume":"8","author":"V Strand","year":"2021","unstructured":"Strand V, et al. Patient-reported outcomes in psoriatic arthritis patients with an inadequate response to biologic disease-modifying antirheumatic drugs: SELECT-PsA 2. Rheumatol Ther. 2021;8(4):1827\u201344.","journal-title":"Rheumatol Ther"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00748-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:03:03Z","timestamp":1742328183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00748-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00748-8","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"20 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lars-Erik Kristensen received grants or contracts from Pfizer, AbbVie, Amgen, Galapagos, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals, consulting fees from Pfizer, AbbVie, Amgen, Galapagos, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals, and honoraria from Pfizer, AbbVie, Amgen, Galapagos, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. Dennis McGonagle received grant funding, support for attending meetings or travel, and support for attending advisory board from Eli Lilly and Company. Martin Rudwaleit received consulting fees from Eli Lilly and Company, Novartis, and UCB, honoraria from AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Novartis, and UCB, and support for attending meetings or travel from Janssen, Novartis, Galapagos, AbbVie, and UCB. Hideto Kameda received grants or contracts from Asahi Kasei, Taisho, Mitsubishi-Tanabe, Eisai, Chugai, Pfizer, and AbbVie, consulting fees from Sanofi, Novartis, and AbbVie, honoraria from AbbVie, Asahi Kasei, Bristol Myers, Boehringer Ingelheim, Chugai, Eisai, Mitsubichi-Tanabe, Janssen, Eli Lilly and Company, Novartis, Pfizer, and UCB, support for participation in data safety monitoring board or advisory board from AbbVie, Astellas, Amgen, Eli Lilly and Company, Sanofi, and UCB, and holds a leadership or fiduciary role in the Japan Spondyloarthritis Society. Josef Smolen received grants or contracts from AbbVie, AstraZeneca, Eli Lilly and Company, Novartis, Galapagos, and Roche, consulting fees from AbbVie, Amgen, Ananda, Astro, BMS, Celltrion, Chugai, Eli Lilly and Company, Gilead, Immunovant, MSD, Novartis, Pfizer, Roche, R-Pharma, Samsung, Sanofi, and UCB, and support for attending meetings or travel from Eli Lilly and Company. Thorsten Holzkaemper, Marcu Ngantcha and Peter Adler are employees and shareholders at Eli Lilly and Company. Joanna Burke was a contract statistician for Eli Lilly and Company via Agile who contributed to the manuscript during development. Joanna Burke was not affiliated to Eli Lilly and Company after the completion of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The studies were compliant with ethical guidelines including the Declaration of Helsinki and other relevant laws and regulations. The three trials were approved by each site\u2019s ethical review committee\/institution review board; names of all principal investigators and participating study sites have been previously published [, , ]. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}